Edition:
United Kingdom

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

17.85USD
13 Dec 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$17.85
Open
$17.90
Day's High
$18.15
Day's Low
$17.45
Volume
327,650
Avg. Vol
340,038
52-wk High
$25.70
52-wk Low
$7.80

Select another date:

Fri, Dec 8 2017

BRIEF-Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules

* IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES

BRIEF-Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​

* Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​

BRIEF-Impax Laboratories says board of co amended and restated bylaws of co

* Impax Laboratories says ‍on and effective Nov 10, 2017, board of co amended and restated bylaws of company - SEC filing

BRIEF-Impax Q3 adjusted earnings per share $0.23

* Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S

BRIEF-Impax gets FDA approval for generic Renvela tablets

* Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg

Amneal, Impax combine to tackle generic drug pricing pressure

Amneal Pharmaceuticals LLC is buying fellow generics drug maker Impax Laboratories Inc in an all-stock deal as a bulwark against a tough drug pricing environment.

UPDATE 3-Amneal, Impax combine to tackle generic drug pricing pressure

* Impax was expected to keep >25 pct stake - analyst (Adds analysts' comments, background on retail pharmacies; updates shares)

BRIEF-IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​

* REQUIRED TO PAY AMNEAL FEE OF $45 MILLION IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​

Drugmakers Amneal, Impax to combine in generics push

Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing environment.

BRIEF-Drugmaker Amneal to combine with Impax Labs

* Transaction expected to generate $200 million of annual cost savings within three years​

Select another date: